Orphazyme to host Interim Report First Half 2021 investor call on August 31, 2021
25 août 2021 08h33 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No. 08/2021Company Registration No. 32266355 Copenhagen – August 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces...
Orphazyme announces publication of results from its Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C in the Journal of Inherited Metabolic Disease
23 août 2021 05h04 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor newsNo. 07/2021Company Registration No. 32266355 Arimoclomol was well-tolerated with a statistically significant and clinically meaningful effect on disease progression ...
New publication date for Orphazyme’s Interim Report H1 2021
05 août 2021 12h11 HE
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No. 06/2021Company Registration No. 32266355 Copenhagen – August 5, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced...
Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research
28 juin 2021 02h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 21/2021Company Registration No. 32266355 Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today...
Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC
28 juin 2021 00h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 20/2021Inside informationCompany Registration No. 32266355 -Significant headcount reduction of global workforce to free resources- -Changes to the...
Major shareholder announcement
24 juin 2021 07h31 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 19/2021Company Registration No. 32266355 Copenhagen, Denmark, June 24, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
Major shareholder announcement
23 juin 2021 05h43 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2021Company Registration No. 32266355 Copenhagen, Denmark, June 23, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C
18 juin 2021 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 16/2021Inside informationCompany Registration No. 32266355 Copenhagen – June 18, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage...
Major shareholder announcement
15 juin 2021 11h05 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 16/2021Company Registration No. 32266355 Copenhagen, Denmark, June 15, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage...
Orphazyme addresses recent trading activity
11 juin 2021 03h42 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 15/2021Company Registration No. 32266355 Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering...